Keywords
Opioid overdose prevention
Naloxone distribution
Syringe service programs
Opioid use disorder
Overdose prevention centers (OPCs)
Categories
Data Availability Statement
All literature and data analyzed during this review were sourced from publicly available databases, specifically PubMed, Scopus, and Web of Science. Additional information was extracted from publicly accessible clinical trial data and World Health Organization (WHO) reports.
How to Cite
Abstract
Background: This systematic review synthesizes evidence on community-based harm reduction programs and their role in addressing the opioid crisis.
Methods: A narrative synthesis was conducted of 78 studies published between January 2012 and April 2023; meta-analysis was precluded by heterogeneity across interventions, populations, and outcomes. Eligible designs included quantitative observational studies, qualitative/mixed-methods studies, program evaluations, and existing systematic/scoping reviews. Interventions examined included syringe service programs (SSPs), overdose education and naloxone distribution (OEND), overdose prevention centers (OPCs), drug-checking services, and low-barrier medications for opioid use disorder (MOUD). Outcomes included overdose mortality, infectious disease transmission, treatment linkage, and feasibility/acceptability.
Results: OEND scale-up was associated with reduced opioid overdose mortality at county and state levels. SSPs were consistently linked to reduced HIV and HCV transmission. OPCs reported no on-site fatal overdoses despite high volumes of supervised consumption. Integrated SSP-MOUD models improved MOUD initiation and retention, though association strength varied by setting and design. Combined approaches showed favorable cost-effectiveness. Persistent barriers included punitive paraphernalia laws, regulatory constraints, stigma, and rural service gaps.
Conclusion: Key gaps remain in implementation science, longitudinal efficacy of newer interventions (OPCs, drug-checking), and stigma-reduction strategies. Policy implications include integrating harm reduction into mainstream health infrastructure via sustained funding, deregulation to expand providers, mobile/mail-based rural access, and public communication to build legitimacy. Across a heterogeneous evidence base, community-based harm reduction consistently associates with reduced overdose mortality and infectious disease burden. Translating this evidence into equitable, sustainable implementation remains the central challenge for public health policy and practice.
References
1. Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry. 2021: 218 [PMID: 32020048, https://doi.org/10.1038/s41380-020-0661-4]
2. Judd D, King CR, Galke C. The Opioid Epidemic: A Review of the Contributing Factors, Negative Consequences, and Best Practices. Cureus. 2023: e41621 [PMID: 37565101, https://doi.org/10.7759/cureus.41621]
3. Csete J. United States drug courts and opioid agonist therapy: Missing the target of overdose reduction. Forensic Sci Int Mind Law. 2020: 100024 [PMID: 34171038, https://doi.org/10.1016/j.fsiml.2020.100024]
4. Kline D, Hepler SA, Krawczyk N, Rivera-Aguirre A, Waller LA, Cerda M. A state-level history of opioid overdose deaths in the United States: 1999-2021. PLoS One. 2024: e0309938 [PMID: 39240938, https://doi.org/10.1371/journal.pone.0309938]
5. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths decreased? Widespread fentanyl saturation and decreased drug use among key drivers. Lancet Reg Health Am. 2025: 101226 [PMID: 41323547, https://doi.org/10.1016/j.lana.2025.101226]
6. Abbasi K. Better health for vulnerable groups, better health for all. J R Soc Med. 2024: 327 [PMID: 39536268, https://doi.org/10.1177/01410768241299771]
7. Davis A, Lembo T, Laurie E, Mutua E, Loosli K, Nthambi M, Nimegeer A, Mnzava K, Msoka EF, Nasuwa F, Melubo M, Shirima G, Matthews L, Hilton S, Mshana SE, Mmbaga BT. How public health crises expose systemic, day-to-day health inequalities in low- and-middle income countries: an example from East Africa. Antimicrob Resist Infect Control. 2022: 34 [PMID: 35164886, https://doi.org/10.1186/s13756-022-01071-5]
8. Tran MTN, Luong QH. Community harm reduction initiatives: Essential investments for illicit drug prevention and control in the future. Lancet Reg Health West Pac. 2022: 100373 [PMID: 35024663, https://doi.org/10.1016/j.lanwpc.2021.100373]
9. Wenger LD, Kral AH, Bluthenthal RN, Morris T, Ongais L, Lambdin BH. Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises. Transl Res. 2021: 159 [PMID: 33746108, https://doi.org/10.1016/j.trsl.2021.03.011]
10. Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015: 25 [PMID: 26245865, https://doi.org/10.1186/s12954-015-0058-x]
11. Adams JM. Making the Case for Syringe Services Programs. Public Health Rep. 2020: 10S [PMID: 32735192, https://doi.org/10.1177/0033354920936233]
12. Behrends CN, Des Jarlais DC, Luhur W, Lu X, Corry GJ, Glick SN, Kapadia SN, Perlman DC, Schackman BR. On-site health service delivery models at syringe services programs in the United States: Results of a national cross-sectional survey. Drug Alcohol Depend Rep. 2025: 100355 [PMID: 40687393, https://doi.org/10.1016/j.dadr.2025.100355]
13. Hanson BL, Porter RR, Zold AL, Terhorst-Miller H. Preventing opioid overdose with peer-administered naloxone: findings from a rural state. Harm Reduct J. 2020: 4 [PMID: 31918740, https://doi.org/10.1186/s12954-019-0352-0]
14. Smart R, Davis CS. Reducing Opioid Overdose Deaths by Expanding Naloxone Distribution and Addressing Structural Barriers to Care. Am J Public Health. 2021: 1382 [PMID: 34464185, https://doi.org/10.2105/AJPH.2021.306376]
15. Stevens A, Keemink JR, Shirley-Beavan S, Khadjesari Z, Artenie A, Vickerman P, Southwell M, Shorter GW. Overdose prevention centres as spaces of safety, trust and inclusion: A causal pathway based on a realist review. Drug Alcohol Rev. 2024: 1573 [PMID: 39104059, https://doi.org/10.1111/dar.13908]
16. Wares JR, Dong J, Gevertz JL, Radunskaya A, Viner K, Wiebe D, Solomon S. Predicting the impact of placing an overdose prevention site in Philadelphia: a mathematical modeling approach. Harm Reduct J. 2021: 110 [PMID: 34717657, https://doi.org/10.1186/s12954-021-00559-4]
17. Ljungholm L, Edin-Liljegren A, Ekstedt M, Klinga C. What is needed for continuity of care and how can we achieve it? - Perceptions among multiprofessionals on the chronic care trajectory. BMC Health Serv Res. 2022: 686 [PMID: 35606787, https://doi.org/10.1186/s12913-022-08023-0]
18. Khan GK, Harvey L, Johnson S, Long P, Kimmel S, Pierre C, Drainoni ML. Integration of a community-based harm reduction program into a safety net hospital: a qualitative study. Harm Reduct J. 2022: 35 [PMID: 35414072, https://doi.org/10.1186/s12954-022-00622-8]
19. Childs E, Biello KB, Valente PK, Salhaney P, Biancarelli DL, Olson J, Earlywine JJ, Marshall BDL, Bazzi AR. Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies. Int J Drug Policy. 2021: 103080 [PMID: 33340947, https://doi.org/10.1016/j.drugpo.2020.103080]
20. Panagiotoglou D, Abrahamowicz M, Buckeridge DL, Caro JJ, Latimer E, Maheu-Giroux M, Strumpf EC. Evaluating Montreal's harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis. BMJ Open. 2021: e053191 [PMID: 34702731, https://doi.org/10.1136/bmjopen-2021-053191]
21. Krieger MS, Goedel WC, Buxton JA, Lysyshyn M, Bernstein E, Sherman SG, Rich JD, Hadland SE, Green TC, Marshall BDL. Use of rapid fentanyl test strips among young adults who use drugs. Int J Drug Policy. 2018: 52 [PMID: 30344005, https://doi.org/10.1016/j.drugpo.2018.09.009]
22. Haegerich TM, Jones CM, Cote PO, Robinson A, Ross L. Evidence for state, community and systems-level prevention strategies to address the opioid crisis. Drug Alcohol Depend. 2019: 107563 [PMID: 31585357, https://doi.org/10.1016/j.drugalcdep.2019.107563]
23. Knaak S, Mantler E, Szeto A. Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions. Healthc Manage Forum. 2017: 111 [PMID: 28929889, https://doi.org/10.1177/0840470416679413]
24. Waqas A, Malik S, Fida A, Abbas N, Mian N, Miryala S, Amray AN, Shah Z, Naveed S. Interventions to Reduce Stigma Related to Mental Illnesses in Educational Institutes: a Systematic Review. Psychiatr Q. 2020: 887 [PMID: 32372401, https://doi.org/10.1007/s11126-020-09751-4]
25. Gronholm PC, Bakolis I, Cherian AV, Davies K, Evans-Lacko S, Girma E, Gurung D, Hanlon C, Hanna F, Henderson C, Kohrt BA, Lempp H, Li J, Loganathan S, Maulik PK, Ma N, Ouali U, Romeo R, Rusch N, Semrau M, Taylor Salisbury T, Votruba N, Wahid SS, Zhang W, Thornicroft G. Toward a multi-level strategy to reduce stigma in global mental health: overview protocol of the Indigo Partnership to develop and test interventions in low- and middle-income countries. Int J Ment Health Syst. 2023: 2 [PMID: 36732828, https://doi.org/10.1186/s13033-022-00564-5]
26. National Academies of Sciences E, Medicine. Pain management and the opioid epidemic. Washington, DC: National Academies Press; 2017.
27. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021: 344 [PMID: 33965972, https://doi.org/10.1097/YCO.0000000000000717]
28. Alvand S, Amin-Esmaeili M, Poustchi H, Roshandel G, Sadeghi Y, Sharifi V, Kamangar F, Dawsey SM, Freedman ND, Abnet CC, Rahimi-Movaghar A, Malekzadeh R, Etemadi A. Prevalence and determinants of opioid use disorder among long-term opiate users in Golestan Cohort Study. BMC Psychiatry. 2023: 958 [PMID: 38129791, https://doi.org/10.1186/s12888-023-05436-x]
29. Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein BS. Opioid use disorder: current trends and potential treatments. Front Public Health. 2023: 1274719 [PMID: 38332941, https://doi.org/10.3389/fpubh.2023.1274719]
30. Lowenstein M, Abrams MP, Crowe M, Shimamoto K, Mazzella S, Botcheos D, Bertocchi J, Westfahl S, Chertok J, Garcia KP, Truchil R, Holliday-Davis M, Aronowitz S. "Come try it out. Get your foot in the door:" Exploring patient perspectives on low-barrier treatment for opioid use disorder. Drug Alcohol Depend. 2023: 109915 [PMID: 37207615, https://doi.org/10.1016/j.drugalcdep.2023.109915]
31. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018: 137 [PMID: 29913516, https://doi.org/10.7326/M17-3107]
32. Wenger LD, Doe-Simkins M, Wheeler E, Ongais L, Morris T, Bluthenthal RN, Kral AH, Lambdin BH. Best practices for community-based overdose education and naloxone distribution programs: results from using the Delphi approach. Harm Reduct J. 2022: 55 [PMID: 35643444, https://doi.org/10.1186/s12954-022-00639-z]
33. Adams JW, Savinkina A, Fox A, Behrends CN, Madushani R, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022: 2635 [PMID: 35315148, https://doi.org/10.1111/add.15883]
34. Ostlund U, Kidd L, Wengstrom Y, Rowa-Dewar N. Combining qualitative and quantitative research within mixed method research designs: a methodological review. Int J Nurs Stud. 2011: 369 [PMID: 21084086, https://doi.org/10.1016/j.ijnurstu.2010.10.005]
35. Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, Kral AH. Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020: 1117 [PMID: 32817603, https://doi.org/10.15585/mmwr.mm6933a2]
36. Kimmel SD, Gaeta JM, Hadland SE, Hallett E, Marshall BDL. Principles of Harm Reduction for Young People Who Use Drugs. Pediatrics. 2021: S240 [PMID: 33386326, https://doi.org/10.1542/peds.2020-023523G]
37. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014: 45 [PMID: 24690082, https://doi.org/10.1186/1471-2288-14-45]
38. Hartling L, Milne A, Hamm MP, Vandermeer B, Ansari M, Tsertsvadze A, Dryden DM. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol. 2013: 982 [PMID: 23683848, https://doi.org/10.1016/j.jclinepi.2013.03.003]
39. Long HA, French DP, Brooks JM. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Research Methods in Medicine & Health Sciences. 2020: 31 https://doi.org/10.1177/2632084320947559]
40. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021: 89 [PMID: 33781348, https://doi.org/10.1186/s13643-021-01626-4]
41. Kahale LA, Elkhoury R, El Mikati I, Pardo-Hernandez H, Khamis AM, Schunemann HJ, Haddaway NR, Akl EA. Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal. F1000Res. 2021: 192 [PMID: 35136567, https://doi.org/10.12688/f1000research.51723.3]
42. Vadiei N, Axon DR, Eckert B. Naloxone Distribution Models in the United States: A Scoping Review. Subst Use Addctn J. 2025: 391 [PMID: 39449273, https://doi.org/10.1177/29767342241289008]
43. World Health O. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva2022.
44. Jakubowski A, Fowler S, Fox AD. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. Addict Sci Clin Pract. 2023: 40 [PMID: 37301953, https://doi.org/10.1186/s13722-023-00394-x]
45. Mezaache S, Turlure F, Fredon N, Le Brun Gadelius M, Micallef J, Frauger E. [Opioid overdose prevention and naloxone diffusion (POP program): Results of an overview conducted among addiction specialized centres]. Therapie. 2023: 605 [PMID: 37012152, https://doi.org/10.1016/j.therap.2023.03.008]
46. van Draanen J, Hamilton J, Morgan J, Maxwell S, Taylor T, Richardson L, Nolan S. Supervised smoking facility access, harm reduction practices, and substance use changes during the COVID-19 pandemic: a community-engaged cross-sectional study. Harm Reduct J. 2023: 101 [PMID: 37525168, https://doi.org/10.1186/s12954-023-00825-7]
47. Kutscher E, Barber Grossi M, LaPolla F, Lee JD. Fentanyl Test Strips for Harm Reduction: A Scoping Review. J Addict Med. 2024: 373 [PMID: 38829042, https://doi.org/10.1097/ADM.0000000000001321]
48. Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani R, Potee RA, Ryan D, Murphy SM, Walley AY, Linas BP. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Netw Open. 2023: e237036 [PMID: 37058306, https://doi.org/10.1001/jamanetworkopen.2023.7036]
49. Ivsins A, MacKinnon L, Bowles JM, Slaunwhite A, Bardwell G. Overdose Prevention and Housing: a Qualitative Study Examining Drug Use, Overdose Risk, and Access to Safer Supply in Permanent Supportive Housing in Vancouver, Canada. J Urban Health. 2022: 855 [PMID: 36044156, https://doi.org/10.1007/s11524-022-00679-7]
50. Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S. Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes. Subst Abuse Rehabil. 2024: 173 [PMID: 39295965, https://doi.org/10.2147/SAR.S475807]
51. Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, Kimmelman J, Martel MO, Eisenberg MJ. The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews. Am J Public Health. 2021: e1 [PMID: 34214412, https://doi.org/10.2105/AJPH.2021.306306]
52. Bohler RM, Freeman PR, Villani J, Hunt T, Linas BS, Walley AY, Green TC, Lofwall MR, Bridden C, Frazier LA, Fanucchi LC, Talbert JC, Chandler R. The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses. Drug Alcohol Depend Rep. 2023: [PMID: 36643788, https://doi.org/10.1016/j.dadr.2022.100126]
53. Osilla KC, Meredith LS, Griffin BA, Martineau M, Hindmarch G, Watkins KE. Design of CLARO+ (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses, Plus): A randomized trial of collaborative care to decrease overdose and suicide risk among patients with co-occurring disorders. Contemp Clin Trials. 2023: 107294 [PMID: 37454728, https://doi.org/10.1016/j.cct.2023.107294]
54. Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, McClung RP, Asher AK. Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them. Am J Prev Med. 2021: S118 [PMID: 34686281, https://doi.org/10.1016/j.amepre.2021.05.044]
55. Fernandez-Vina MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State Laws Governing Syringe Services Programs and Participant Syringe Possession, 2014-2019. Public Health Rep. 2020: 128S [PMID: 32735195, https://doi.org/10.1177/0033354920921817]
56. Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, Horvath T, Kennedy GE, Des Jarlais DC. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013: 2878 [PMID: 23975473, https://doi.org/10.1007/s10461-013-0593-y]
57. Goedel WC, King MRF, Lurie MN, Galea S, Townsend JP, Galvani AP, Friedman SR, Marshall BDL. Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study. Clin Infect Dis. 2020: 1096 [PMID: 31143944, https://doi.org/10.1093/cid/ciz321]
58. Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerda M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019". Int J Drug Policy. 2022: 103786 [PMID: 35934583, https://doi.org/10.1016/j.drugpo.2022.103786]
59. Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, Glick SN, Hamblin M, Holcomb S, Mosse D, Oliphant-Wells T, Shim MM. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus. 2020: 356 [PMID: 31403907, https://doi.org/10.1080/08897077.2019.1635557]
60. Lambdin BH, Kan D, Kral AH. Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs. Subst Abuse Treat Prev Policy. 2022: 51 [PMID: 35841036, https://doi.org/10.1186/s13011-022-00483-1]
61. Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS, Ramirez F, Guzman M, Spratt S, Marcus P, Fox AD. Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. J Addict Med. 2022: 447 [PMID: 34775441, https://doi.org/10.1097/ADM.0000000000000934]
62. Kapadia SN, Griffin JL, Waldman J, Ziebarth NR, Schackman BR, Behrends CN. A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study. J Gen Intern Med. 2021: 1898 [PMID: 33469774, https://doi.org/10.1007/s11606-020-06409-6]
63. Forchuk C, Serrato J, Scott L. Identifying barriers and facilitators for implementing harm reduction strategies for methamphetamine use into hospital settings. Front Health Serv. 2023: 1113891 [PMID: 36926504, https://doi.org/10.3389/frhs.2023.1113891]
64. Lindenfeld Z, Hagan H, Chang JE. Exploring Barriers and Facilitators to Integrating a Harm Reduction Approach to Substance Use in Three Medical Settings. J Gen Intern Med. 2023: 3273 [PMID: 37227658, https://doi.org/10.1007/s11606-023-08231-2]
65. Ezell JM, Ompad DC, Walters S. How urban and rural built environments influence the health attitudes and behaviors of people who use drugs. Health Place. 2021: 102578 [PMID: 33964805, https://doi.org/10.1016/j.healthplace.2021.102578]
66. Ashworth M, Thunstrom L, Clancy GL, Thompson RA, Johnson D, Fletcher E. Addressing rural and non-rural substance use disorder stigma: Evidence from a national randomized controlled trial. Addict Behav Rep. 2024: 100541 [PMID: 38550604, https://doi.org/10.1016/j.abrep.2024.100541]
67. Davis CS, Carr DH, Samuels EA. Paraphernalia Laws, Criminalizing Possession and Distribution of Items Used to Consume Illicit Drugs, and Injection-Related Harm. Am J Public Health. 2019: 1564 [PMID: 31536408, https://doi.org/10.2105/AJPH.2019.305268]
68. Rouhani S, Schneider KE, Weicker N, Whaley S, Morris M, Sherman SG. NIMBYism and Harm Reduction Programs: Results from Baltimore City. J Urban Health. 2022: 717 [PMID: 35641715, https://doi.org/10.1007/s11524-022-00641-7]
69. Rosen JG, Thompson E, Tardif J, Collins AB, Marshall BDL, Park JN. "Make yourself un-NIMBY-able": stakeholder perspectives on strategies to mobilize public and political support for overdose prevention centers in the United States of America. Harm Reduct J. 2024: 40 [PMID: 38355641, https://doi.org/10.1186/s12954-024-00955-6]
70. Tempalski B, Friedman R, Keem M, Cooper H, Friedman SR. NIMBY localism and national inequitable exclusion alliances: The case of syringe exchange programs in the United States. Geoforum. 2007: 1250 [PMID: 18978931, https://doi.org/10.1016/j.geoforum.2007.03.012]
71. Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. J Rural Health. 2019: 108 [PMID: 29923637, https://doi.org/10.1111/jrh.12307]
72. Kolak MA, Chen YT, Joyce S, Ellis K, Defever K, McLuckie C, Friedman S, Pho MT. Rural risk environments, opioid-related overdose, and infectious diseases: A multidimensional, spatial perspective. Int J Drug Policy. 2020: 102727 [PMID: 32513621, https://doi.org/10.1016/j.drugpo.2020.102727]
73. Remien RH, Bauman LJ, Mantell JE, Tsoi B, Lopez-Rios J, Chhabra R, DiCarlo A, Watnick D, Rivera A, Teitelman N, Cutler B, Warne P. Barriers and facilitators to engagement of vulnerable populations in HIV primary care in New York City. J Acquir Immune Defic Syndr. 2015: S16 [PMID: 25867774, https://doi.org/10.1097/QAI.0000000000000577]
74. Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: Health services experiences among people who inject drugs. Int J Drug Policy. 2018: 104 [PMID: 29715589, https://doi.org/10.1016/j.drugpo.2018.04.004]
75. AH LKSCC. Harm reduction: An approach to reducing risky health behaviours in adolescents. Paediatr Child Health. 2008: 53 [PMID: 19119355, https://doi.org/10.1093/pch/13.1.53]
76. Substance A, Mental Health Services A. Medications for opioid use disorder: Treatment Improvement Protocol (TIP) 63. Rockville, MD2021.
77. Englander H, Dobbertin K, Lind BK, Nicolaidis C, Graven P, Dorfman C, Korthuis PT. Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. J Gen Intern Med. 2019: 2796 [PMID: 31410816, https://doi.org/10.1007/s11606-019-05251-9]
78. Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017: 28 [PMID: 28521829, https://doi.org/10.1186/s12954-017-0154-1]
79. Salmon AM, van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction. 2010: 676 [PMID: 20148794, https://doi.org/10.1111/j.1360-0443.2009.02837.x]
80. Patel K. The Importance of Data-Driven Decision-Making in Public Health. International Journal of Computer Trends and Technology. 2024: 27 https://doi.org/10.14445/22312803/ijctt-v72i5p103]
81. Steinwachs DM. Transforming public health systems: using data to drive organizational capacity for quality improvement and efficiency. EGEMS (Wash DC). 2014: 1175 [PMID: 25995990, https://doi.org/10.13063/2327-9214.1175]
82. Emerson B, Haden M. Public Health and the Harm Reduction Approach to Illegal Psychoactive Substances ☆. Reference Module in Biomedical Sciences2018.
83. Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, Smith LR, Strathdee SA, Wakeman SE, Venkataramani AS. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019: e1002969 [PMID: 31770387, https://doi.org/10.1371/journal.pmed.1002969]
84. Lee JH, Wheeler DC, Zimmerman EB, Hines AL, Chapman DA. Urban-Rural Disparities in Deaths of Despair: A County-Level Analysis 2004-2016 in the U.S. Am J Prev Med. 2023: 149 [PMID: 38584644, https://doi.org/10.1016/j.amepre.2022.08.022]
85. Raver E, Retchin SM, Li Y, Carlo AD, Xu WY. Rural-urban differences in out-of-network treatment initiation and engagement rates for substance use disorders. Health Serv Res. 2024: e14299 [PMID: 38456488, https://doi.org/10.1111/1475-6773.14299]
86. McGinty E, Pescosolido B, Kennedy-Hendricks A, Barry CL. Communication Strategies to Counter Stigma and Improve Mental Illness and Substance Use Disorder Policy. Psychiatr Serv. 2018: 136 [PMID: 28967320, https://doi.org/10.1176/appi.ps.201700076]
87. Rich KM, Bia J, Altice FL, Feinberg J. Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV? Curr HIV/AIDS Rep. 2018: 266 [PMID: 29774442, https://doi.org/10.1007/s11904-018-0396-x]
88. Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Ann Intern Med. 2017: 268 [PMID: 27919103, https://doi.org/10.7326/M16-2149]
89. Tseregounis IE, Henry SG. Assessing opioid overdose risk: a review of clinical prediction models utilizing patient-level data. Transl Res. 2021: 74 [PMID: 33762186, https://doi.org/10.1016/j.trsl.2021.03.012]
90. Socia KM, Stone R, Palacios WR, Cluverius J. Focus on prevention: The public is more supportive of “overdose prevention sites” than they are of “safe injection facilities”. Criminology & Public Policy. 2021: 729 https://doi.org/10.1111/1745-9133.12566]
91. Kerr T, Small W, Wood E. The public health and social impacts of drug market enforcement: A review of the evidence. International Journal of Drug Policy. 2005: 210 https://doi.org/10.1016/j.drugpo.2005.04.005]
92. Holder P. https://doi.org/10.1377/hlthaff.2019.00580]
93. Frieden TR, Lee CT, Lamorde M, Nielsen M, McClelland A, Tangcharoensathien V. The road to achieving epidemic-ready primary health care. Lancet Public Health. 2023: e383 [PMID: 37120262, https://doi.org/10.1016/S2468-2667(23)00060-9]
94. Benjamin GC. The Future of Public Health: Ensuring An Adequate Infrastructure. Milbank Q. 2023: 637 [PMID: 37096604, https://doi.org/10.1111/1468-0009.12637]
95. DeSalvo K, Parekh A, Hoagland GW, Dilley A, Kaiman S, Hines M, Levi J. Developing a Financing System to Support Public Health Infrastructure. Am J Public Health. 2019: 1358 [PMID: 31415208, https://doi.org/10.2105/AJPH.2019.305214]
96. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020: e1920622 [PMID: 32022884, https://doi.org/10.1001/jamanetworkopen.2019.20622]
97. Mohsin K, Mula-Hussain L, Gilson R. HealthCare Access Barrier (HCAB) framework for the barriers to cancer care during conflicts: perspective from Iraq. BMJ Oncol. 2024: e000252 [PMID: 39886185, https://doi.org/10.1136/bmjonc-2023-000252]
98. Allen EM, Call KT, Beebe TJ, McAlpine DD, Johnson PJ. Barriers to Care and Health Care Utilization Among the Publicly Insured. Med Care. 2017: 207 [PMID: 27579910, https://doi.org/10.1097/MLR.0000000000000644]
99. Olayinka F, Sauer M, Menning L, Summers D, Wonodi C, Mackay S, MacDonald NE, Peter Figueroa J, Andriamitantsoa B, Bonsu G, Haldar P, Lindstrand A, Shimp L, Ia Strategic Priority 2 Commitment DWG. Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2). Vaccine. 2024: S43 [PMID: 36528448, https://doi.org/10.1016/j.vaccine.2022.11.038]
100. Fu JS, Wang R. Multiple pathways to organizational legitimacy: Information visibility, organizational listening, and cross-sector partnerships. Public Relations Review. 2024: https://doi.org/10.1016/j.pubrev.2024.102484]
101. Taylor S. Political epidemiology: strengthening socio-political analysis for mass immunisation - lessons from the smallpox and polio programmes. Glob Public Health. 2009: 546 [PMID: 19367477, https://doi.org/10.1080/17441690701727850]
102. Mackey KM. Effectiveness of Syringe Services Programs: A Systematic Review. Washington (DC)2023.
103. Roux P, Jauffret-Roustide M, Donadille C, Briand Madrid L, Denis C, Celerier I, Chauvin C, Hamelin N, Maradan G, Carrieri MP, Protopopescu C, Lalanne L, Auriacombe M, Group CS. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. Int J Epidemiol. 2023: 562 [PMID: 35690956, https://doi.org/10.1093/ije/dyac120]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Eloghosa Aisosaa Nosa-Ihaza, Ssembuusi Allan Francis